IIM
MCID: MYS005
MIFTS: 56

Myositis (IIM)

Categories: Bone diseases, Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 57 12 73 20 29 54 6 42 44 15 17 70 32
Idiopathic Inflammatory Myopathy 20 43 58
Idiopathic Inflammatory Myositis 20 43 58
Idiopathic Inflammatory Myopathies 43 70
Iim 57 20
Imm 20 58
Myopathy, Familial Idiopathic Inflammatory; Iim 57
Myopathy, Familial Idiopathic Inflammatory 57
Idiopathic Inflammatory Myopathy, Familial 20
Myopathies Idiopathic Inflammatory 54
Inflammatory Myopathy, Idiopathic 43
Inflammatory Disorder of Muscle 12

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
myositis:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:633
OMIM® 57 160750
MeSH 44 D009220
NCIt 50 C27578
SNOMED-CT 67 26889001
ICD10 32 M60 M60.9 M63.2
UMLS via Orphanet 71 C0751356
Orphanet 58 ORPHA98482
MedGen 41 C0027121
SNOMED-CT via HPO 68 128496001 249939004 263681008
UMLS 70 C0027121 C0751356

Summaries for Myositis

MedlinePlus Genetics : 43 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.The primary symptom of idiopathic inflammatory myopathy is muscle weakness, which develops gradually over a period of weeks to months or even years. Other symptoms include joint pain and general tiredness (fatigue).There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis.Polymyositis and dermatomyositis involve weakness of the muscles closest to the center of the body (proximal muscles), such as the muscles of the hips and thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathy may find it difficult to climb stairs, get up from a seated position, or lift items above their head. In some cases, muscle weakness may make swallowing or breathing difficult.Polymyositis and dermatomyositis have similar symptoms, but dermatomyositis is distinguished by a reddish or purplish rash on the eyelids, elbows, knees, or knuckles. Sometimes, abnormal calcium deposits form hard, painful bumps under the skin (calcinosis).In sporadic inclusion body myositis, the muscles most affected are those of the wrists and fingers and the front of the thigh. Affected individuals may frequently stumble while walking and find it difficult to grasp items. As in dermatomyositis and polymyositis, swallowing can be difficult.

MalaCards based summary : Myositis, also known as idiopathic inflammatory myopathy, is related to inclusion body myositis and pyomyositis, and has symptoms including muscle weakness, myoclonus and back pain. An important gene associated with Myositis is FAM111B (FAM111 Trypsin Like Peptidase B), and among its related pathways/superpathways is tRNA Aminoacylation. The drugs Infliximab and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and bone, and related phenotypes are myositis and proximal muscle weakness

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

GARD : 20 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis, which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors. Treatment is supportive and based on the signs and symptoms present in each person.

MedlinePlus : 42 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 73 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

More information from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1012)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 33.4 SERPINA3 HLA-B FYCO1 APP
2 pyomyositis 32.4 PIK3C2A MB
3 granulomatous myositis 32.3 TRIM21 PIK3C2A
4 polymyositis 32.2 TARS1 PIK3C2A MB HARS1 DYSF
5 antisynthetase syndrome 32.2 TRIM21 TARS1 IFIH1 HARS1
6 foot drop 32.0 TTN DYSF
7 epidemic pleurodynia 31.9 PIK3C2A MB
8 myopathy 31.5 TTN TRIM21 SERPINA3 PIK3C2A MB HLA-B
9 exanthem 31.4 TRIM21 PIK3C2A IFIH1
10 childhood type dermatomyositis 31.3 TRIM21 PIK3C2A IFIH1 HARS1
11 myocarditis 31.1 TTN PIK3C2A MB HLA-B DMD
12 autoimmune disease 31.0 TRIM21 PSMB9 IFIH1 HLA-B FBL
13 muscular dystrophy 31.0 TTN PIK3C2A MB DYSF DMD CAPN3
14 giant cell myocarditis 30.8 MB HLA-B
15 gas gangrene 30.8 SERPINA3 PIK3C2A MB DMD
16 adult dermatomyositis 30.8 TRIM21 IFIH1
17 respiratory failure 30.7 TTN SERPINA3 PIK3C2A DMD
18 limb-girdle muscular dystrophy 30.7 TTN DYSF CAPN3
19 myoglobinuria 30.6 PIK3C2A MB DMD
20 neuromuscular disease 30.5 TTN SERPINA3 MB DYSF DMD CAPN3
21 miyoshi muscular dystrophy 30.5 TTN PIK3C2A DYSF DMD CAPN3
22 peripheral nervous system disease 30.5 SERPINA3 HARS1 DMD APP
23 nonaka myopathy 30.5 TTN SERPINA3 DYSF DMD CAPN3
24 muscular dystrophy, duchenne type 30.4 TTN PIK3C2A MB DMD
25 muscular dystrophy, becker type 30.4 PIK3C2A DYSF DMD CAPN3
26 myofibrillar myopathy 30.3 TTN SERPINA3 DYSF DMD CAPN3
27 progressive muscular dystrophy 30.2 MB DMD
28 emery-dreifuss muscular dystrophy 30.2 TTN DYSF DMD CAPN3
29 atrioventricular block 30.2 TTN TRIM21 PIK3C2A
30 muscular disease 30.0 TTN SERPINA3 PIK3C2A MB IFIH1 DYSF
31 muscular dystrophy-dystroglycanopathy , type c, 5 30.0 TTN DYSF CAPN3
32 localized lipodystrophy 30.0 DYSF DMD
33 dysferlinopathy 30.0 DYSF CAPN3
34 anterior compartment syndrome 29.9 MB DYSF
35 acute interstitial pneumonia 29.9 TRIM21 IFIH1 HARS1
36 batten-turner congenital myopathy 29.9 TTN DYSF DMD
37 leiomyosarcoma 29.8 SERPINA3 PSMB9 MB
38 polyclonal hypergammaglobulinemia 29.8 TRIM21 SERPINA3
39 tibial muscular dystrophy 29.8 TTN DYSF DMD CAPN3
40 diffuse scleroderma 29.8 TRIM21 FBL
41 interstitial myocarditis 29.8 PIK3C2A MB DMD
42 muscular dystrophy, limb-girdle, autosomal recessive 2 29.8 TTN DYSF DMD CAPN3
43 muscular dystrophy, congenital, lmna-related 29.8 TTN DYSF DMD CAPN3
44 spinal muscular atrophy 29.8 FBL DMD CAPN3 AARS1
45 malignant hyperthermia 29.6 PIK3C2A MB DMD
46 isolated elevated serum creatine phosphokinase levels 29.6 TTN PIK3C2A MB DYSF DMD CAPN3
47 fibrodysplasia ossificans progressiva 11.7
48 congenital disorder of glycosylation, type iim 11.7
49 myositis ossificans 11.6
50 slc35a2-congenital disorder of glycosylation 11.4

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

31
# Description HPO Frequency HPO Source Accession
1 myositis 31 HP:0100614
2 proximal muscle weakness 31 HP:0003701

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Muscle:
myositis
proximal muscle weakness

Clinical features from OMIM®:

160750 (Updated 05-Apr-2021)

UMLS symptoms related to Myositis:


muscle weakness; myoclonus; back pain; myalgia; torticollis; sciatica; muscle cramp; muscle rigidity; muscle spasticity

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.12 CAPN3 PIK3C2A
2 Decreased viability GR00055-A-2 10.12 CAPN3 PIK3C2A
3 Decreased viability GR00055-A-3 10.12 CAPN3 PIK3C2A
4 Decreased viability GR00221-A-1 10.12 PIK3C2A
5 Decreased viability GR00221-A-2 10.12 PIK3C2A TTN
6 Decreased viability GR00221-A-4 10.12 ACVR1 DYSF PIK3C2A TTN
7 Decreased viability GR00240-S-1 10.12 PIK3C2A TRIM21
8 Decreased viability GR00249-S 10.12 FBL HLA-B PIK3C2A SERPINA3
9 Decreased viability GR00301-A 10.12 DYSF
10 Decreased viability GR00342-S-1 10.12 PIK3C2A TTN
11 Decreased viability GR00342-S-2 10.12 PIK3C2A
12 Decreased viability GR00342-S-3 10.12 PIK3C2A TTN
13 Decreased viability GR00386-A-1 10.12 FYCO1 MB
14 Decreased viability GR00402-S-2 10.12 DMD TARS1
15 Increased ionizing radiation sensitivity GR00232-A-1 8.92 ACVR1 HARS1 TRIM21 TTN

MGI Mouse Phenotypes related to Myositis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.28 AARS1 ACVR1 APP CAPN3 DMD DYSF

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 2, Phase 3 170277-31-3
2
Simvastatin Approved Phase 2, Phase 3 79902-63-9 54454
3
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
6
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
8
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
Azathioprine Approved Phase 3 446-86-6 2265
11
Abatacept Approved Phase 3 332348-12-6 10237
12
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
13
Sodium citrate Approved, Investigational Phase 3 68-04-2
14
Zoledronic Acid Approved Phase 3 118072-93-8 68740
15
Denosumab Approved Phase 3 615258-40-7
16
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
17
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
18
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616
20
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
21
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
22
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3 303-98-0 5281915
23
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
27 Gastrointestinal Agents Phase 2, Phase 3
28 Dermatologic Agents Phase 2, Phase 3
29 Pharmaceutical Solutions Phase 2, Phase 3
30 Trace Elements Phase 2, Phase 3
31 Nutrients Phase 2, Phase 3
32 Vitamins Phase 2, Phase 3
33 Ubiquinone Phase 2, Phase 3
34 Micronutrients Phase 2, Phase 3
35 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
36 Methylprednisolone Acetate Phase 3
37 Calcineurin Inhibitors Phase 3
38 Antimetabolites Phase 3
39 Citrate Phase 3
40 Immunoglobulins Phase 3
41 Antibodies Phase 3
42 Diphosphonates Phase 3
43 Antibodies, Monoclonal Phase 3
44 Anti-Infective Agents Phase 3
45 Antifungal Agents Phase 3
46 Antibiotics, Antitubercular Phase 3
47 Anti-Bacterial Agents Phase 3
48 Antineoplastic Agents, Immunological Phase 2, Phase 3
49 Antirheumatic Agents Phase 2, Phase 3
50 Immunologic Factors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
2 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
3 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
4 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
5 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
6 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
7 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
8 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
9 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
10 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
11 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Active, not recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
12 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
13 A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
14 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
15 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
16 A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS) Not yet recruiting NCT04789070 Phase 3 Sirolimus;Placebo
17 Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva Not yet recruiting NCT04577820 Phase 3 garetosmab
18 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Terminated NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
19 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
20 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
21 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
22 Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM) Completed NCT02753530 Phase 2 Arimoclomol
23 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
24 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
25 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
26 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
27 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
28 Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis Recruiting NCT03912428 Phase 1, Phase 2 Celecoxib
29 A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome Recruiting NCT03215927 Phase 2 Abatacept
30 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
31 Saracatinib Trial TO Prevent FOP Recruiting NCT04307953 Phase 2 AZD0530 Difumarate;Matching placebo
32 A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan on Left Atrial Volume Index in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. Active, not recruiting NCT04687111 Phase 2 Sacubitril-Valsartan;Valsartan
33 A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT02279095 Phase 2 Palovarotene dose level 1;Palovarotene dose level 2;Palovarotene dose level 3;Palovarotene dose level 4
34 A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva Active, not recruiting NCT03188666 Phase 2 REGN2477;Matching placebo
35 A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT02979769 Phase 2 Palovarotene dose level 1;Palovarotene dose level 2
36 A Randomised, Phase IIa Treatment Delayed-start Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult Idiopathic Inflammatory Myopathy Not yet recruiting NCT04208464 Phase 2 Baricitinib;Baricitinib
37 A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Low-dose Interleukin-2 in Combination With Standard Therapy Compared to Standard Therapy Alone in Adults With Active Idiopathic Inflammatory Myopathy Not yet recruiting NCT04237987 Phase 2 Interleukin-2;ciclosporin and corticosteroid
38 Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy Not yet recruiting NCT04062019 Phase 2 Interleukin-2
39 A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Terminated NCT02521792 Phase 2 Palovarotene
40 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis Withdrawn NCT03710941 Phase 2 REGN2477+REGN1033;Matching placebo
41 Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis Unknown status NCT02483845 Phase 1 Natalizumab
42 Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. Completed NCT01519349 Phase 1
43 An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis Completed NCT03440034 Phase 1 Pioglitazone
44 Kinesio Taping Effects Applied With Different Directions and Tensions on Electromyography, Electroencephalography, Local Temperature and Muscle Strength Completed NCT02501915 Phase 1
45 An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects Completed NCT04829773 Phase 1 Palovarotene;midazolam
46 Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Active, not recruiting NCT04421677 Phase 1 Phenylbutyrate Oral Tablet
47 A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Not yet recruiting NCT04659031 Phase 1 ABC008
48 Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects Not yet recruiting NCT04818398 Phase 1 DS-6016a;Placebo
49 High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial Terminated NCT00278564 Phase 1 Cyclophosphamide;Mesna;ATG(rabbit);Methylprednisolone;G-CSF;Rituxan
50 Risk of Muscle Damage in Cancer Patients Exposed to the Influenza Vaccine While Receiving Checkpoint Inhibitor Therapies: A Nested Case Control Study Using Claims Data Unknown status NCT03644498

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carisoprodol
Chlorphenesin
chlorphenesin carbamate
Chlorzoxazone
cyclobenzaprine
Cyclobenzaprine hydrochloride
metaxalone
Methocarbamol
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine
tizanidine hydrochloride

Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

40
Lung, Skeletal Muscle, Bone, Skin, T Cells, Heart, Breast

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 9935)
# Title Authors PMID Year
1
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. 57 61
9550481 1998
2
Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. 61 42
33458584 2020
3
Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. 42
33579248 2021
4
Idiopathic inflammatory myopathy human derived cells retain their ability to increase mitochondrial function. 42
33216776 2020
5
Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress. 54 61
20236612 2010
6
Gemfibrozil-induced myositis in a patient with normal renal function. 54 61
19934390 2010
7
Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. 61 54
19833747 2009
8
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. 61 54
19644880 2009
9
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. 54 61
18628284 2009
10
Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease? 54 61
19285864 2009
11
[Hypothyroidism with leading myopathy in a patient suffering from systemic lupus erythematosus and Hashimoto's thyroiditis]. 61 54
18936898 2008
12
Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. 61 54
18974565 2008
13
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity? 54 61
18534849 2008
14
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. 61 54
18420712 2008
15
Adults with eosinophilic myositis and calpain-3 mutations. 61 54
18299526 2008
16
Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. 54 61
17979987 2007
17
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. 54 61
17764014 2007
18
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. 61 54
17277004 2007
19
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report]. 61 54
18320790 2007
20
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. 54 61
17763431 2007
21
Rituximab for refractory polymyositis: an open-label prospective study. 61 54
17722224 2007
22
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. 54 61
17665459 2007
23
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. 61 54
17606177 2007
24
Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. 61 54
17616993 2007
25
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. 61 54
17405833 2007
26
Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis. 61 54
17360184 2007
27
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 54 61
17420473 2007
28
Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. 54 61
17359364 2007
29
Genetic determinants of statin intolerance. 54 61
17376224 2007
30
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 61 54
17265504 2007
31
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. 61 54
17077152 2006
32
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. 54 61
17057271 2006
33
Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. 61 54
16856153 2006
34
Presymptomatic neuromuscular disorders disclosed following statin treatment. 61 54
16864763 2006
35
CAPN3 mutations in patients with idiopathic eosinophilic myositis. 61 54
16607617 2006
36
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. 54 61
17039976 2006
37
Neurological manifestations of dengue virus infection. 61 54
16524594 2006
38
Serum creatine kinase levels and renal function measures in exertional muscle damage. 61 54
16679975 2006
39
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 54 61
16431335 2006
40
Antisynthetase syndrome associated with sarcoidosis. 54 61
17043379 2006
41
Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. 61 54
16224247 2005
42
Role of major histocompatibility complex class I molecules in autoimmune myositis. 54 61
16224250 2005
43
Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. 54 61
16115818 2005
44
Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. 61 54
16102434 2005
45
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. 54 61
15983828 2005
46
Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 61 54
16052580 2005
47
Benign acute childhood myositis. 54 61
15973022 2005
48
Beta-chemokine receptor expression in idiopathic inflammatory myopathies. 54 61
15772970 2005
49
Changes of single fiber electromyography in patients with inflammatory myopathies. 54 61
15844301 2005
50
Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. 54 61
15634233 2005

Variations for Myositis

ClinVar genetic disease variations for Myositis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FAM111B NM_198947.4(FAM111B):c.1462del (p.Cys488fs) Deletion Likely pathogenic 599012 rs1565191262 GRCh37: 11:58893032-58893032
GRCh38: 11:59125559-59125559

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.17 TARS1 NARS1 HARS1 AARS1

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 TTN TRIM21 TARS1 PSMB9 PIK3C2A NARS1
2 extracellular exosome GO:0070062 9.4 TTN TARS1 SERPINA3 PSMB9 PIK3C2A NARS1
3 astrocyte projection GO:0097449 9.16 DMD APP

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.46 TARS1 NARS1 HARS1 AARS1
2 tRNA aminoacylation GO:0043039 8.96 TARS1 AARS1
3 tRNA aminoacylation for protein translation GO:0006418 8.92 TARS1 NARS1 HARS1 AARS1

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.06 TTN TRIM21 MB IFIH1 FYCO1 DYSF
2 nucleotide binding GO:0000166 9.97 TTN TARS1 PIK3C2A NARS1 IFIH1 HARS1
3 ATP binding GO:0005524 9.86 TTN TARS1 PIK3C2A NARS1 IFIH1 HARS1
4 structural constituent of muscle GO:0008307 9.33 TTN DMD CAPN3
5 ligase activity GO:0016874 9.26 TARS1 NARS1 HARS1 AARS1
6 aminoacyl-tRNA ligase activity GO:0004812 8.92 TARS1 NARS1 HARS1 AARS1

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....